Skip to main content
. 2021 Oct 19;11:747950. doi: 10.3389/fonc.2021.747950

Table 2.

Change in tumor characteristics before vs. after the combined therapy.

  Patient/case no.
1 2 3 4 5 6 7 8 9 10
ΔTTV (ml) −739.7 −60.9 −433.9 −556.5 −1,054.5 −105.5 −170 −18.8 −1,072.7 −494.37
Time (days) 145 84 43 97 48 107 86 93 75 61
ΔTTV/day −5.1 −0.73 −10.09 −5.74 −21.97 −0.99 −1.98 −0.2 −14.3 −8.1
ΔTTV/SLV*day −0.48% −0.06% −0.77% −0.43% −1.48% −0.07% −0.17% −0.02% −1.21% −0.58%
ΔFRLV (ml) 35.8 32.1 −2.1 −41.8 98.2 2.02 −70 −145 35.1 0
ΔFRLV/day 0.25 0.38 −0.05 −0.43 2.05 0.02 −0.81 −1.56 0.47 0
ΔFRLV/SLV*day 0.02% 0.03% 0.00% −0.03% 0.14% 0.00% −0.07% −0.14% 0.04% 0.00%
ΔPVTTv (ml) −30.07 −65.9 −6.9 −56.27 −9.35 −7.75 −44.89 −17.61
ΔPVTTv/day −0.21 −0.78 −0.16 −0.58 −0.19 −0.08 −0.6 −0.29

Estimated standard liver volume (SLV) calculated using the Urata formula: SLV = 706.2 × BSA + 2.4. Body surface area (BSA) calculated using the DuBois formula: BSA (m2) = BW (kg) 0.425 × BH (cm) 0.725 × 0.007184. Preoperative height (BH, measured to the nearest 1 cm), body weight (BW, measured to the nearest 1 kg).

FRLV, functional residue liver volume; PVTTv, portal vein tumor thrombus volume; SLV, standard liver volume; TTV, total tumor volume.